{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T20:03:00Z","timestamp":1778011380424,"version":"3.51.4"},"reference-count":58,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["ERJ Open Res"],"accepted":{"date-parts":[[2025,5,13]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:p>\n                    Community-acquired pneumonia (CAP) remains a major global contributor of human morbidity and mortality, with\n                    <jats:italic>Streptococcus pneumoniae<\/jats:italic>\n                    as the leading bacterial cause across all ages. While pneumococcal vaccines reduce the impact of pneumococcal disease, the burden remains high, in both invasive and non-invasive disease, partly due to infection with pneumococcal serotypes not included in currently available vaccines. CAP also leads to significant healthcare costs, a burden likely to grow with ageing populations.\n                  <\/jats:p>\n                  <jats:p>To inform vaccine development and public health policies regarding vaccination, additional data are needed to understand the morbidity and mortality associated with specific pneumococcal serotypes, and the effectiveness of currently available vaccines.<\/jats:p>\n                  <jats:p>This paper describes the design and rationale of the Pneumococcal Pneumonia Epidemiology, Urine Serotyping and Mental Outcomes (PNEUMO) study Europe. This multicentre, prospective, population-based, active surveillance observational study will enrol approximately 9000 adult patients hospitalised with all-cause CAP at 50 academic hospital sites across six countries in Europe, focusing on pneumococcal disease and non-pneumonia invasive pneumococcal disease. The primary goal is to estimate the incidence of pneumococcal pneumonia and serotype prevalence among adults in Europe. The study will also track in-hospital outcomes and, in a subset of approximately 600 patients, follow-up assessing the trajectory of functional and cognitive outcomes over six months. Besides the typing of isolates when available, serotype-specific urinary antigen detection assays will be used to identify serotypes from both invasive and non-invasive disease.<\/jats:p>","DOI":"10.1183\/23120541.00237-2025","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:15:51Z","timestamp":1749014151000},"page":"00237-2025","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Rationale and design of the Pneumococcal Pneumonia Epidemiology, Urine Serotyping and Mental Outcomes (PNEUMO) study Europe"],"prefix":"10.1183","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6974-9165","authenticated-orcid":false,"given":"Cristina","family":"Prat-Aymerich","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Hessels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dian","family":"Karssen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-6135","authenticated-orcid":false,"given":"Kelly D.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastiaan","family":"Hullegie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rianne","family":"Jahja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Rodriguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno","family":"Fran\u00e7ois","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2285-9970","authenticated-orcid":false,"given":"Francesco","family":"Blasi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Chalmers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grit","family":"Barten-Neiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Franch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madelyn","family":"Ruggieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Todd D.","family":"Swarthout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-4635","authenticated-orcid":false,"given":"Henri","family":"van Werkhoven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the PNEUMO Europe Investigators and Collaborators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"81","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"2026021204000812000_11.6.00237-2025.1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41572-021-00259-0","article-title":"Pneumonia","volume":"7","author":"Torres","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026021204000812000_11.6.00237-2025.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00176-2"},{"key":"2026021204000812000_11.6.00237-2025.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405870"},{"key":"2026021204000812000_11.6.00237-2025.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500245"},{"key":"2026021204000812000_11.6.00237-2025.5","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2009.129502"},{"key":"2026021204000812000_11.6.00237-2025.6","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1183\/13993003.00735-2022","article-title":"ERS\/ESICM\/ESCMID\/ALAT guidelines for the management of severe community-acquired pneumonia","volume":"61","author":"Martin-Loeches","year":"2023","journal-title":"Eur Respir J"},{"key":"2026021204000812000_11.6.00237-2025.7","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"2026021204000812000_11.6.00237-2025.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2018.02.007"},{"key":"2026021204000812000_11.6.00237-2025.9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-020-00479-7"},{"key":"2026021204000812000_11.6.00237-2025.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71081-3"},{"key":"2026021204000812000_11.6.00237-2025.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1209165"},{"key":"2026021204000812000_11.6.00237-2025.12","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-211767"},{"key":"2026021204000812000_11.6.00237-2025.13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0220453"},{"key":"2026021204000812000_11.6.00237-2025.14","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.2217\/fmb.15.80","article-title":"The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?","volume":"10","author":"van Werkhoven","year":"2015","journal-title":"Future Microbiol"},{"key":"2026021204000812000_11.6.00237-2025.15","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.3390\/microorganisms9071428","article-title":"Pediatric invasive pneumococcal disease three years after PCV13 introduction in the national immunization plan-the continued importance of serotype 3","volume":"9","author":"Silva-Costa","year":"2021","journal-title":"Microorganisms"},{"key":"2026021204000812000_11.6.00237-2025.16","unstructured":"US Centers for Disease Control and Prevention (CDC) . Streptococcus pneumoniae Detection and Serotyping Using PCR. Date last accessed: 14 October 2024. www.cdc.gov\/strep-lab\/php\/pneumococcus\/serotyping-using-pcr.html"},{"key":"2026021204000812000_11.6.00237-2025.17","doi-asserted-by":"crossref","first-page":"e0011422","DOI":"10.1128\/msphere.00114-22","article-title":"Development and validation of a sensitive and robust multiplex antigen capture assay to quantify Streptococcus pneumoniae serotype-specific capsular polysaccharides in urine","volume":"7","author":"Rajam","year":"2022","journal-title":"mSphere"},{"key":"2026021204000812000_11.6.00237-2025.18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17576180.2024.2357030","article-title":"Qualification of a 21-valent pneumococcal urine antigen detection assay and development of clinical positivity cutoffs","volume":"16","author":"Choudhury","year":"2024","journal-title":"Bioanalysis"},{"key":"2026021204000812000_11.6.00237-2025.19","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00064-12"},{"key":"2026021204000812000_11.6.00237-2025.20","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00137412"},{"key":"2026021204000812000_11.6.00237-2025.21","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa158"},{"key":"2026021204000812000_11.6.00237-2025.22","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1080\/21645515.2016.1264548","article-title":"Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?","volume":"13","author":"van Werkhoven","year":"2017","journal-title":"Hum Vaccin Immunother"},{"key":"2026021204000812000_11.6.00237-2025.23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060273"},{"key":"2026021204000812000_11.6.00237-2025.24","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1586\/14760584.2016.1132171","article-title":"Pneumococcal conjugate vaccine use in adults","volume":"15","author":"Isturiz","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"2026021204000812000_11.6.00237-2025.25","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3390\/microorganisms11112813","article-title":"Epidemiology of pneumococcal pneumonia in Louisville, Kentucky, and its estimated burden of disease in the United States","volume":"11","author":"Ramirez","year":"2023","journal-title":"Microorganisms"},{"key":"2026021204000812000_11.6.00237-2025.26","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1016\/j.vaccine.2022.02.081","article-title":"Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community-acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay","volume":"40","author":"LeBlanc","year":"2022","journal-title":"Vaccine"},{"key":"2026021204000812000_11.6.00237-2025.27","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.3390\/microorganisms9112245","article-title":"Serotypes in adult pneumococcal pneumonia in spain in the era of conjugate vaccines","volume":"9","author":"Fern\u00e1ndez-Delgado","year":"2021","journal-title":"Microorganisms"},{"key":"2026021204000812000_11.6.00237-2025.28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.arbres.2010.06.014","article-title":"Community acquired pneumonia. New guidelines of the Spanish society of chest diseases and thoracic surgery (SEPAR)","volume":"46","author":"Men\u00e9ndez","year":"2010","journal-title":"Arch Bronconeumol"},{"key":"2026021204000812000_11.6.00237-2025.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.08.007"},{"key":"2026021204000812000_11.6.00237-2025.30","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2019-213725"},{"key":"2026021204000812000_11.6.00237-2025.31","first-page":"838","article-title":"Prevalence, clinical severity, and serotype distribution of pneumococcal pneumonia among adults hospitalized with community-acquired pneumonia in Tennessee and Georgia, 2018\u20132022","volume":"79","author":"Self","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021204000812000_11.6.00237-2025.32","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7104a1"},{"key":"2026021204000812000_11.6.00237-2025.33","unstructured":"European Center for Disease Prevention and Control (ECDC) . Vaccine schedule. ECDC Europa. Date last accessed: 14 October 2024. https:\/\/vaccine-schedule.ecdc.europa.eu\/"},{"key":"2026021204000812000_11.6.00237-2025.34","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S1473-3099(24)00344-X","article-title":"Safety, tolerability, and immunogenicity of an adult pneumococcal conjugate vaccine, V116 (STRIDE-3): a randomised, double-blind, active comparator controlled, international phase 3 trial","volume":"24","author":"Platt","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2026021204000812000_11.6.00237-2025.35","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1093\/cid\/ciae383","article-title":"A phase 3 clinical study to evaluate the safety, tolerability, and immunogenicity of V116 in pneumococcal vaccine-experienced adults 50 years of age or older (stride-6)","volume":"79","author":"Scott","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2026021204000812000_11.6.00237-2025.36","doi-asserted-by":"crossref","first-page":"793","DOI":"10.15585\/mmwr.mm7336a3","article-title":"Use of 21-calent pneumococcal conjugate vaccine among US adults: recommendations of the Advisory Committee on Immunization Practices \u2014 United States, 2024","volume":"73","author":"Kobayashi","year":"2024","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026021204000812000_11.6.00237-2025.37","unstructured":"European Medicines Agency . Capxavive. Date last accessed: 6 May 2025. www.ema.europa.eu\/en\/medicines\/human\/EPAR\/capvaxive"},{"key":"2026021204000812000_11.6.00237-2025.38","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"2026021204000812000_11.6.00237-2025.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"2026021204000812000_11.6.00237-2025.40","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.5.377"},{"key":"2026021204000812000_11.6.00237-2025.41","doi-asserted-by":"publisher","DOI":"10.1086\/511159"},{"key":"2026021204000812000_11.6.00237-2025.42","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2462070712"},{"key":"2026021204000812000_11.6.00237-2025.43","unstructured":"World Health Organization . International Classification of Diseases 11th Revision. Date last accessed: 14 October 2024. www.who.int\/standards\/classifications\/classification-of-diseases"},{"key":"2026021204000812000_11.6.00237-2025.44","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-018-3515-9"},{"key":"2026021204000812000_11.6.00237-2025.45","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00113-2022"},{"key":"2026021204000812000_11.6.00237-2025.46","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00937-20"},{"key":"2026021204000812000_11.6.00237-2025.47","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00540-21"},{"key":"2026021204000812000_11.6.00237-2025.48","first-page":"195","article-title":"The effects of the COVID-19 pandemic on community respiratory virus activity","volume":"21","author":"Chow","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"2026021204000812000_11.6.00237-2025.49","doi-asserted-by":"publisher","DOI":"10.1016\/S2589-7500(21)00077-7"},{"key":"2026021204000812000_11.6.00237-2025.50","doi-asserted-by":"crossref","first-page":"106204","DOI":"10.1016\/j.jinf.2024.106204","article-title":"Surveillance of invasive pneumococcal disease in Spain exploring the impact of the COVID-19 pandemic (2019\u20132023)","volume":"89","author":"P\u00e9rez-Garc\u00eda","year":"2024","journal-title":"J Infect"},{"key":"2026021204000812000_11.6.00237-2025.51","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00703-2022"},{"key":"2026021204000812000_11.6.00237-2025.52","unstructured":"Swarthout T , Hessels L , Jahja R , et al. Effect of pneumococcal and all-cause community acquired pneumonia (CAP) on cognitive function: results from the PNEUMO EU study. Cape Town, International Society of Pneumonia and Pneumococcal Diseases, 2024."},{"key":"2026021204000812000_11.6.00237-2025.53","unstructured":"Swarthout TD , Hessels L , Jahja R , et al. Effect of pneumococcal and all-cause community acquired pneumonia (CAP) on 6-month function: results from the PNEUMO-EU study. Cape Town, International Society of Pneumonia and Pneumococcal Diseases, 2024."},{"key":"2026021204000812000_11.6.00237-2025.54","unstructured":"Hessels L , Jahja R , Hullegie S , et al. Blood biomarkers to predict etiology and severity in adults hospitalized with community acquired pneumonia (CAP). Cape Town, International Society of Pneumonia and Pneumococcal Diseases, 2024."},{"key":"2026021204000812000_11.6.00237-2025.55","unstructured":"Hessels L , Hullegie S , Jahja R , et al. Epidemiolog\u00eda de la Neumon\u00eda Adquirida en la Comunidad y Enfermedad Neumoc\u00f3cica Invasiva en Espa\u00f1a durante la pandemia COVID-19. Resultados preliminares del estudio PNEUMO Europe. XXVI Congreso Nacional de la Sociedad Espa\u00f1ola de Enfermedades Infecciosas y Microbiolog\u00eda Cl\u00ednica Santiago de Compostela; 2023."},{"key":"2026021204000812000_11.6.00237-2025.56","doi-asserted-by":"crossref","unstructured":"Hessels L , Hullegie S , Jahja R , et al. Epidemiology and etiology of community-acquired pneumonia in adults across Europe during the COVID-19 pandemic. European Congress of Clinical Microbiology and Infectious Diseases Copenhagen; 2023.","DOI":"10.1183\/13993003.congress-2023.OA4864"},{"key":"2026021204000812000_11.6.00237-2025.57","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA4867"},{"key":"2026021204000812000_11.6.00237-2025.58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2023.OA4864"}],"container-title":["ERJ Open Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/23120541.00237-2025","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:00:27Z","timestamp":1770897627000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/23120541.00237-2025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":58,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,12,8]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1183\/23120541.00237-2025"],"URL":"https:\/\/doi.org\/10.1183\/23120541.00237-2025","relation":{},"ISSN":["2312-0541"],"issn-type":[{"value":"2312-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}